Gelonghui, March 2, 丨 Saisheng Pharmaceutical (6600.HK) rapidly rose in the dark market segment. It is now reported at HK$19.9, up 5.8% from the issue price of HK$18.8. The company is a biopharmaceutical company with an integrated platform for product development and commercialization. In 2018 and 2019, revenue was 1,408 million yuan and 1,708 million yuan respectively, profits were 535 million yuan and 614 million yuan respectively, and net tangible assets per share were HK$2.08-2.34. About 116 million shares were sold globally in this listing, of which 57.993 million shares were sold in Hong Kong and 57.9915 million shares were sold internationally. Each lot of 500 shares had a winning rate of 3%. The shares sold in Hong Kong were subscribed 1,068 times, with a net capital of HK$2,0395 million. A number of cornerstone investors, including Taiping Asset Management (Hong Kong), have subscribed for a total of 55.13 million shares, accounting for about 8.13% of the issued share capital after the sale was completed.